Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA Lung RCT
NCT04966663Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Mar 2022
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Health Network. Primary endpoint: Relapse Free Survival at 2 years. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04966663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966663.